SMMT vs XNCR
SMMT: A biopharmaceutical company dedicated to the clinical advancement of its lead bispecific antibody, ivonescimab, for oncology applications. XNCR: Xencor is a clinical-stage biopharma using proprietary protein engineering to develop next-generation bispecific antibodies for cancer and autoimmune conditions.
Side-by-side fundamentals
| Metric | SMMT | XNCR | Edge |
|---|---|---|---|
| Price as of 2026-07-27 close | $13.10 | $20.21 | |
| Market cap as of 2026-08-03 | $10.5B | $1.5B | |
| PEG as of 2026-08-03 | -1.08 | n/a | |
| Net margin as of 2026-08-03 | -9027.1% | -177.1% | XNCR higher |
| Operating margin as of 2026-08-03 | -8108.3% | -222.4% | XNCR higher |
| ROE as of 2026-08-03 | -168.9% | -28.8% | XNCR higher |
| ROA as of 2026-08-03 | -141.9% | -20.5% | XNCR higher |
| Debt / equity as of 2026-08-03 | 0.00 | 0.21 | SMMT lower |
| Revenue growth (YoY) as of 2026-08-03 | n/a | -25.4% | |
| Revenue CAGR (3y) SEC XBRL | n/a | -8.6% | |
| Beta as of 2026-08-03 | -1.34 | 1.51 | |
| 1-year return as of 2026-07-27 close | -54.3% | +142.9% | XNCR higher |
Fundamentals: market data, as of 2026-08-03. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-27.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.